DRB18

Overview

DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity.

Application

Products | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GLUT

Product Information

• Catalog No.: HY-145963
• CAS No.: 2863686-81-9
• Molecular Formula: C22H23ClN2O2
• Molecular Weight: 382.88
• Purity: 99.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source